Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Peritoneal Metastases

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Our aim was to analyze the safety and efficacy of iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (iCRS-HIPEC) in patients with peritoneal recurrence from different tumor types.

PATIENTS AND METHODS: Data on indications, intraoperative findings and postoperative outcome of all patients treated with iCRS-HIPEC at our Institution were reviewed.

RESULTS: Between 2010-2018, 10 iCRS-HIPEC procedures for peritoneal recurrence in eight patients were performed. The median peritoneal cancer index was 14.5 (range=2-33). Completeness of cytoreduction was CC0-1 in most cases (9/10). Three grade III-IV complications (two intestinal fistulas, one bleeding) were recorded and there was no operative mortality. After a median follow-up of 19.5 months, six patients experienced recurrence after a median of 12.5 months.

CONCLUSION: iCRS-HIPEC is a safe procedure in selected patients with recurrent peritoneal surface malignancies. Selection criteria still remain questionable and need to be further evaluated in large cooperative multi-institution studies.

Original languageEnglish
Pages (from-to)5521-5524
Number of pages4
JournalAnticancer Research
Volume38
Issue number9
DOIs
Publication statusPublished - Sep 2018

    Fingerprint

Keywords

  • Adult
  • Aged
  • Cytoreduction Surgical Procedures/adverse effects
  • Female
  • Humans
  • Hyperthermia, Induced/adverse effects
  • Italy
  • Male
  • Middle Aged
  • Peritoneal Neoplasms/secondary
  • Postoperative Complications/etiology
  • Recurrence
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Young Adult

Cite this